Kindred Biosciences Inc (NASDAQ:KIN) Insider Richard Chin Sells 40,000 Shares

Share on StockTwits

Kindred Biosciences Inc (NASDAQ:KIN) insider Richard Chin sold 40,000 shares of the stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $10.28, for a total transaction of $411,200.00. Following the transaction, the insider now owns 2,146,071 shares of the company’s stock, valued at approximately $22,061,609.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Richard Chin also recently made the following trade(s):

  • On Friday, June 1st, Richard Chin sold 40,000 shares of Kindred Biosciences stock. The stock was sold at an average price of $10.13, for a total transaction of $405,200.00.
  • On Wednesday, May 30th, Richard Chin sold 12,610 shares of Kindred Biosciences stock. The stock was sold at an average price of $10.00, for a total transaction of $126,100.00.
  • On Friday, May 25th, Richard Chin sold 3,060 shares of Kindred Biosciences stock. The stock was sold at an average price of $10.00, for a total transaction of $30,600.00.
  • On Friday, May 18th, Richard Chin sold 2,400 shares of Kindred Biosciences stock. The stock was sold at an average price of $10.00, for a total transaction of $24,000.00.
  • On Monday, May 7th, Richard Chin sold 1,730 shares of Kindred Biosciences stock. The stock was sold at an average price of $10.01, for a total transaction of $17,317.30.
  • On Wednesday, May 9th, Richard Chin sold 1,930 shares of Kindred Biosciences stock. The stock was sold at an average price of $10.01, for a total transaction of $19,319.30.
  • On Tuesday, May 1st, Richard Chin sold 20,000 shares of Kindred Biosciences stock. The stock was sold at an average price of $9.05, for a total transaction of $181,000.00.

Shares of Kindred Biosciences stock traded down $0.45 on Friday, hitting $13.10. The stock had a trading volume of 169,100 shares, compared to its average volume of 133,927. Kindred Biosciences Inc has a one year low of $6.55 and a one year high of $13.80. The stock has a market capitalization of $370.87 million, a price-to-earnings ratio of -10.65 and a beta of 0.11.

Kindred Biosciences (NASDAQ:KIN) last issued its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.36). analysts forecast that Kindred Biosciences Inc will post -1.53 earnings per share for the current year.

A number of brokerages recently weighed in on KIN. EuroPacific Canada began coverage on shares of Kindred Biosciences in a research note on Wednesday, May 23rd. They issued a “buy” rating and a $16.75 target price on the stock. BidaskClub raised shares of Kindred Biosciences from a “hold” rating to a “buy” rating in a research note on Saturday, April 14th. ValuEngine raised shares of Kindred Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, July 5th. Zacks Investment Research upgraded shares of Kindred Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, May 5th. Finally, CL King upgraded shares of Kindred Biosciences from a “neutral” rating to a “buy” rating in a research report on Monday, July 9th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $14.95.

A number of large investors have recently added to or reduced their stakes in the stock. Sit Investment Associates Inc. bought a new stake in Kindred Biosciences in the second quarter valued at $752,000. Citigroup Inc. lifted its position in Kindred Biosciences by 2,575.3% during the first quarter. Citigroup Inc. now owns 31,007 shares of the biopharmaceutical company’s stock valued at $268,000 after buying an additional 29,848 shares during the period. Dimensional Fund Advisors LP lifted its position in Kindred Biosciences by 0.4% during the first quarter. Dimensional Fund Advisors LP now owns 1,365,002 shares of the biopharmaceutical company’s stock valued at $11,807,000 after buying an additional 5,587 shares during the period. New York State Common Retirement Fund lifted its position in Kindred Biosciences by 6.2% during the first quarter. New York State Common Retirement Fund now owns 243,249 shares of the biopharmaceutical company’s stock valued at $2,104,000 after buying an additional 14,285 shares during the period. Finally, B. Riley Financial Inc. purchased a new position in Kindred Biosciences during the first quarter valued at $1,120,000. Institutional investors and hedge funds own 62.62% of the company’s stock.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc, a biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline includes small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates comprise Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

See Also: What is a closed-end mutual fund (CEF)?

Insider Buying and Selling by Quarter for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.